RT Journal
A1 Kuehn BM
T1 TArgeting autism-like symptoms
JF JAMA
JO JAMA
YR 2012
FD June 27
VO 307
IS 24
SP 2578
OP 2578
DO 10.1001/jama.2012.7065
UL http://dx.doi.org/10.1001/jama.2012.7065
AB 
The discovery of elevated signaling of the metabotropic glutamate receptor subtype 5 (mGluR5) in mice with a fragile X–like disorder led scientists to probe whether mGluR5 antagonists might reduce some of the behavioral symptoms exhibited by these mice. When animal studies suggested that such compounds could improve symptoms, scientists launched clinical trials of mGluR5 antagonists for patients with fragile X. Because many patients with fragile X also have a diagnosis of autism, the animal findings also led to questions about whether the compounds could reduce some behavioral problems associated with autism.